CL2020001123A1 - Anticuerpos anti-cd40 para el uso en el tratamiento del síndrome de sjögren. - Google Patents

Anticuerpos anti-cd40 para el uso en el tratamiento del síndrome de sjögren.

Info

Publication number
CL2020001123A1
CL2020001123A1 CL2020001123A CL2020001123A CL2020001123A1 CL 2020001123 A1 CL2020001123 A1 CL 2020001123A1 CL 2020001123 A CL2020001123 A CL 2020001123A CL 2020001123 A CL2020001123 A CL 2020001123A CL 2020001123 A1 CL2020001123 A1 CL 2020001123A1
Authority
CL
Chile
Prior art keywords
antibodies
syndrome
treatment
sjögren
therapies
Prior art date
Application number
CL2020001123A
Other languages
English (en)
Inventor
Pascal Espie
Peter Gergely
James Rush
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2020001123A1 publication Critical patent/CL2020001123A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA DIVULGACIÓN SE REFIERE A MÉTODOS, REGÍMENES DE TRATAMIENTO, USOS, EQUIPOS Y TERAPIAS PARA TRATAR EL SÍNDROME DE SJÖGREN, MEDIANTE EL EMPLEO DE ANTICUERPOS ANTI–CD40.
CL2020001123A 2017-11-03 2020-04-28 Anticuerpos anti-cd40 para el uso en el tratamiento del síndrome de sjögren. CL2020001123A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762581212P 2017-11-03 2017-11-03
US201862644939P 2018-03-19 2018-03-19

Publications (1)

Publication Number Publication Date
CL2020001123A1 true CL2020001123A1 (es) 2020-10-30

Family

ID=64572395

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020001123A CL2020001123A1 (es) 2017-11-03 2020-04-28 Anticuerpos anti-cd40 para el uso en el tratamiento del síndrome de sjögren.

Country Status (13)

Country Link
US (1) US20190153111A1 (es)
EP (1) EP3704158A1 (es)
JP (2) JP2021501748A (es)
KR (1) KR20200074993A (es)
CN (1) CN111263771A (es)
AU (2) AU2018361743A1 (es)
BR (1) BR112020008379A2 (es)
CA (1) CA3076872A1 (es)
CL (1) CL2020001123A1 (es)
IL (1) IL273848A (es)
MX (1) MX2020004411A (es)
TW (1) TW201922783A (es)
WO (1) WO2019087094A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR117091A1 (es) 2018-11-19 2021-07-07 Bristol Myers Squibb Co Anticuerpos monoclonales antagonistas contra cd40 y sus usos
CN116234909A (zh) * 2020-08-21 2023-06-06 上海药明生物技术有限公司 Cd40激动剂抗体和使用方法
US20230331860A1 (en) * 2020-08-25 2023-10-19 Bristol-Myers Squibb Company Method of Treating an Autoimmune Disease with Antagonistic CD40 Monoclonal Antibodies
WO2023056297A1 (en) * 2021-09-28 2023-04-06 Viela Bio, Inc. Cd40l-specific tn3-derived scaffolds for the treatment and prevention of sjogren's syndrome

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
PT1707627E (pt) 2003-12-25 2013-01-24 Kyowa Hakko Kirin Co Ltd Mutante antagonista de anticorpo anti-cd40
EP1854810A1 (en) 2006-05-09 2007-11-14 PanGenetics B.V. Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody
US8080248B2 (en) * 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
SI3178851T1 (sl) 2010-03-31 2020-09-30 Boehringer Inhelheim International Gmbh Anti-CD40 protitelesa
JP2013543384A (ja) * 2010-10-05 2013-12-05 ノバルティス アーゲー 抗−ｉｌ１２ｒベータ１抗体ならびに自己免疫性および炎症性疾患の処置おけるその使用
AR083847A1 (es) * 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
US20140004131A1 (en) * 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
TWI681969B (zh) * 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
US10100129B2 (en) * 2014-11-21 2018-10-16 Bristol-Myers Squibb Company Antibodies against CD73 and uses thereof
AU2016329057A1 (en) * 2015-09-30 2018-04-12 Janssen Biotech, Inc. Antagonistic antibodies specifically binding human CD40 and methods of use

Also Published As

Publication number Publication date
BR112020008379A2 (pt) 2020-11-03
JP2022137233A (ja) 2022-09-21
AU2018361743A1 (en) 2020-04-09
AU2022201425A1 (en) 2022-03-24
IL273848A (en) 2020-05-31
MX2020004411A (es) 2020-08-06
JP2021501748A (ja) 2021-01-21
TW201922783A (zh) 2019-06-16
CN111263771A (zh) 2020-06-09
CA3076872A1 (en) 2019-05-09
JP7357120B2 (ja) 2023-10-05
WO2019087094A1 (en) 2019-05-09
RU2020117365A3 (es) 2021-12-24
US20190153111A1 (en) 2019-05-23
RU2020117365A (ru) 2021-12-03
EP3704158A1 (en) 2020-09-09
KR20200074993A (ko) 2020-06-25

Similar Documents

Publication Publication Date Title
CL2020001123A1 (es) Anticuerpos anti-cd40 para el uso en el tratamiento del síndrome de sjögren.
DOP2019000180A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
PH12017501521A1 (en) Anti-dll3 chimeric antigen receptors and methods of use
CO2017002170A2 (es) Terapia de combinación para tratar un paramixovirus
BR112017006664A2 (pt) terapias de combinação
EA201990293A1 (ru) Мультиспецифичные антитела против cd40 и cd137
NZ731467A (en) Anti-tim3 antibodies and methods of use
BR112017019738A2 (pt) macrociclos peptidomiméticos e usos dos mesmos
BR112017005598A2 (pt) macrociclos peptidomiméticos e usos dos mesmos
BR112017007379A2 (pt) moléculas de anticorpo para pd-l1 e usos das mesmas
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
PH12018501153A1 (en) Novel anti-claudin antibodies and methods of use
EA201692529A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
ECSP17081322A (es) Moduladores alostéricos positivos del receptor muscarínico m2
ZA201902320B (en) 17alpha,21-diesters of cortexolone for use in the treatment of tumors
PH12017500825A1 (en) Anti-cldn chimeric antigen receptors and methods of use
MX2017006464A (es) Combinaciones de inhibidor de tlr e inhibidor de tirosina cinasa de bruton.
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
CL2018001715A1 (es) Reguladores del cftr y métodos para su uso
PH12017501930A1 (en) Calicheamicin contructs and methods of use
CL2021001829A1 (es) Anticuerpos anti–cd40 para el uso en el tratamiento de hidradenitis supurativa
PH12016501434A1 (en) Compositions for use in the treatment of allergic conditions
EP3549582A3 (en) Novel capsazepine analogs for the treatment of cancer and other proliferative diseases
CL2018001716A1 (es) Reguladores del cftr y métodos para su uso
MX2019003314A (es) Metodos de tratamiento de la elevacion de dominio 3 de inmunoglobulina de celula t y mucina (tim-3).